Literature DB >> 19593599

Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study.

Shunsei Hirohata1, Yoshinori Kanai, Akiko Mitsuo, Yoshiaki Tokano, Hiroshi Hashimoto.   

Abstract

Psychiatric manifestations are relatively common in systemic lupus erythematosus (SLE) patients. Since there are factors causing psychiatric manifestations other than SLE, the diagnosis of lupus psychosis (LP) is often difficult. Previous studies disclosed that cerebrospinal fluid (CSF) IL-6 was elevated in SLE patients with neuropsychiatric manifestation. The current studies were therefore designed to examine the efficacy of CSF IL-6 in diagnosis of LP. Multicenter retrospective study was performed with 45 SLE patients who showed psychiatric manifestations between 1993 and 2000. The diagnosis of LP and psychosis due to causes other than SLE (non-LP) was confirmed by retrospective review of the clinical records. Thirty-two of the 45 patients were reconfirmed as LP in the retrospective study. Receiver operating characteristic curve analysis revealed that the sensitivity and specificity of CSF IL-6 for diagnosis of LP were 87.5% and 92.3%, respectively, at the cut-off value of 4.3 pg/ml. These results indicate that CSF IL-6 might be an effective measure in diagnosing LP, although exclusion of infectious meningoencephalitis and cerebrovascular accident is necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593599     DOI: 10.1007/s10067-009-1226-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

Review 1.  Cerebral disease in systemic lupus erythematosus.

Authors:  E N Harris; G R Hughes
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement.

Authors:  E Trysberg; H Carlsten; A Tarkowski
Journal:  Lupus       Date:  2000       Impact factor: 2.911

3.  Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity.

Authors:  S Hirohata; S Hirose; T Miyamoto
Journal:  Arch Intern Med       Date:  1985-10

4.  Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus.

Authors:  Yoshiyuki Arinuma; Tamiko Yanagida; Shunsei Hirohata
Journal:  Arthritis Rheum       Date:  2008-04

5.  Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.

Authors:  S Hirohata; T Miyamoto
Journal:  Arthritis Rheum       Date:  1990-05

6.  Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system.

Authors:  D Torre; C Zeroli; G Ferraro; F Speranza; R Tambini; R Martegani; G P Fiori
Journal:  Scand J Infect Dis       Date:  1992

Review 7.  Reversible focal neurological deficits in systemic lupus erythematosus: report of 2 cases and review of the literature.

Authors:  Miho Kimura; Kaori Aramaki; Tatsuhiko Wada; Kazuo Nishi; Reiko Matsushita; Nobuko Iizuka; Atsushi Hashimoto; Sumiaki Tanaka; Akira Ishikawa; Hirahito Endo; Shunsei Hirohata
Journal:  J Neurol Sci       Date:  2008-06-05       Impact factor: 3.181

8.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

9.  Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus.

Authors:  K Isshi; S Hirohata
Journal:  Arthritis Rheum       Date:  1998-10

10.  Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; G W Williams; A D Steinberg
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

View more
  27 in total

Review 1.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus.

Authors:  Cynthia Aranow; Betty Diamond; Meggan Mackay
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 3.  Future prospects in biologic therapy for systemic lupus erythematosus.

Authors:  William Stohl
Journal:  Nat Rev Rheumatol       Date:  2013-09-10       Impact factor: 20.543

Review 4.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

Review 5.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 6.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 7.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

Review 8.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 9.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

Review 10.  Cytokine disturbances in systemic lupus erythematosus.

Authors:  Noam Jacob; William Stohl
Journal:  Arthritis Res Ther       Date:  2011-07-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.